Today: 1 May 2026

Real-time market monitoring

Browse Category

NYSE:JNJ 28 November 2025 - 11 December 2025

Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson stock hit a 52-week high of about $208 on December 11, 2025, lifting its market cap above $500 billion after a rally that outpaced the S&P 500. The surge followed strong oncology trial results, new drug approvals, and optimism about offsetting Stelara sales declines. Legal risks and pricing pressures remain. JNJ’s dividend yield stands near 2.5%.

11 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson (JNJ) Stock After the Bell on December 10, 2025 – And What to Watch Before the December 11 Open

Johnson & Johnson closed at $206.54 on Dec. 10, up 3.3% and less than 1% below its record high, after strong multiple myeloma drug data. After-hours trading edged the stock to $206.90, but premarket indications early Dec. 11 showed a drop to $202.50 on light volume. Year-to-date, JNJ has gained nearly 40%. The company faces ongoing talc litigation and regulatory scrutiny.

11 December 2025

Earnings Reports·NYSE:JNJ·Stock Market

Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson shares rose nearly 2% to about $204 on December 10, 2025, after new Phase 3 data showed its Tecvayli and Darzalex combo cut the risk of multiple myeloma progression or death by 83%. The company has filed for FDA approval, while investors weigh growth in oncology against ongoing talc litigation. JNJ stock is up over 38% year to date, outpacing healthcare peers.

10 December 2025

Financial Forecasts·NYSE:JNJ·Pharmaceuticals·Stock Market

Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Johnson & Johnson shares closed at $199.96 on December 9, down 0.8% after touching $205.54 intraday. After the bell, the company reported Phase 3 data showing its TECVAYLI® + DARZALEX FASPRO® combination cut multiple myeloma progression or death risk by 83%. JNJ paid a $1.30 quarterly dividend, marking 63 years of dividend growth. Analyst consensus sees modest upside, with targets near $203–207.

10 December 2025

Dividends·Health News·NYSE:JNJ·Stock Market

Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson shares closed at $201.62 on December 8, 2025, up nearly 40% year to date and valuing the company at about $486 billion. The stock surged after a Q3 earnings beat, raised full-year guidance, and a surprise plan to spin off its DePuy Synthes orthopaedics unit. JNJ remains a key driver of recent Dow gains. Technical models project up to 16% further upside by March 2026.

9 December 2025

Earnings Reports·NYSE:JNJ·Stock Market

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly shares closed at $998 on December 8, down 1.3%, marking a seventh straight decline and leaving the stock about 10% below its recent high. The company reported a 15% dividend increase, secured Chinese reimbursement for Mounjaro, and saw Nobel laureate Carolyn Bertozzi return to its board. Competition and price cuts in weight-loss drugs weighed on the stock.

9 December 2025

Dividends·Earnings Reports·NASDAQ:GPCR·NYSE:JNJ·NYSE:LLY·Pharmaceuticals·Stock Market

Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson shares traded at $202.48 on December 8, 2025, near a 52-week high and up nearly 35% over the past year. The company raised its 2025 sales guidance to $93–94 billion and EPS to about $10.80–$10.90 after beating Q2 and Q3 expectations. Analysts’ 12-month targets average just above the current price, with a consensus “Buy” rating. J&J faces Stelara patent loss, talc lawsuits, and MedTech pricing pressure in China.

8 December 2025

Financial Forecasts·NYSE:JNJ·Pharmaceuticals

Johnson & Johnson (JNJ) Stock Near Record Highs: What to Know Before the Market Opens on December 8, 2025

Johnson & Johnson closed Friday at just over $201, near its 52-week high of $207.81, with a market cap around $486 billion. The company reported positive CAR-T therapy data at ASH 2025 and gained access to China’s new drug reimbursement catalog. The board declared a Q4 dividend of $1.30 per share. About 67,670 federal talc lawsuits remain unresolved after a judge rejected J&J’s latest $10 billion settlement offer.

8 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson shares closed at $201.90 on December 5, 2025, less than 3% below their 52-week high. The stock has climbed about 35% over the past year, fueled by earnings beats, acquisitions, and new clinical data. The company faces large talc litigation verdicts and plans to spin off its orthopaedics unit. Market capitalization stands near $485 billion.

6 December 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

Johnson & Johnson (JNJ) Stock on December 6, 2025: Price, Latest News, Analyst Targets and Dividend Outlook

Johnson & Johnson shares closed at $201.93 on December 5, 2025, near a record high after climbing about 35% over the past year. The stock’s 2025 rally outpaced major indexes, driven by strong earnings and portfolio changes, but ongoing talc litigation remains a risk. JNJ trades at roughly 19 times trailing earnings, with a market cap near $480 billion. Institutional ownership is close to 70%.

6 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson (JNJ) Stock: Price, Latest News, Analyst Forecasts and Dividend Outlook – December 5, 2025

Johnson & Johnson shares closed near $201 on December 5, 2025, up about 40% year-to-date and just below record highs. Guggenheim raised its price target to $227 after strong Q3 results and increased full-year guidance. Institutional ownership remains high amid ongoing litigation and a planned spinoff. Most analyst targets now cluster near current prices.

5 December 2025

Dividends·NYSE:JNJ

Johnson & Johnson (JNJ) Stock on December 4, 2025: Price Action, Latest News, Analyst Targets and 2026 Outlook

Johnson & Johnson shares closed at about $202 on December 4, 2025, down 1.6% and just below recent highs. The stock has gained around 40% over the past year, with a market cap near $487 billion and a dividend yield of about 2.5%. No major news drove the day’s dip; profit-taking and mixed institutional moves were cited.

4 December 2025

NYSE:JNJ·Price Forecast·Stock Market

Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson traded near $206 on Wednesday, close to its 52-week high after a 40% rally this year. Guggenheim reiterated a Buy rating and $206 target, citing strong multiple myeloma trial results. Barclays raised its target to $197 but kept an Equal Weight rating. The company launched a vision-care campaign with Naomi Watts and received European approval for its autoimmune drug IMAAVY.

4 December 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson closed at $206.92 on December 2, just below its record high of $207.56 from November 26. The company’s market cap stands near $500 billion after a 30% year-to-date stock surge, outpacing the S&P 500. Recent gains follow strong earnings, higher 2025 guidance, a new EU drug approval, and a $3.05 billion oncology acquisition.

2 December 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

Johnson & Johnson (JNJ) Stock News & Forecast: EU Drug Approval, $3B Cancer Deal and Dividend Strength – December 1, 2025

Johnson & Johnson shares traded near $206, close to a 52-week high, after the European Commission approved IMAAVY (nipocalimab) for generalized myasthenia gravis. The stock has gained about 47% year-to-date, far outpacing the S&P 500. Market cap stands near $500 billion. Analyst consensus puts fair value around $200.

1 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson (JNJ) Stock Near Record Highs: What Investors Should Know Before the December 1, 2025 Market Open

Johnson & Johnson closed at $206.92 on Friday, just below its all-time intraday high of $207.81 set in late November. The stock has gained 17.6% over the past three months and 43.5% year-to-date, far outpacing the S&P 500. Market capitalization stands near $500 billion. Shares open December 1 with investors watching for new analyst commentary and ongoing legal and spin-off risks.

30 November 2025

NYSE:JNJ·Stock Market

Johnson & Johnson (JNJ) Stock Near Record Highs: Is the $500 Billion Healthcare Giant Still a Buy in 2025?

Johnson & Johnson stock surged to an all-time high close of $207.56 on November 26, 2025, lifting its market value above $500 billion for the first time. Shares are up about 45% year-to-date, far outpacing the S&P 500. The rally follows strong Q3 results, raised guidance, and momentum from new drugs, despite ongoing litigation and product setbacks. JNJ now trades at 19.8 times trailing earnings.

30 November 2025

NYSE:JNJ·Stock Market

Johnson & Johnson (JNJ) Stock Near Record Highs: Today’s News, Earnings, Dividend and Talc Risks – November 29, 2025

Johnson & Johnson shares closed just above $206 on November 29, 2025, near a record high and pushing the company’s market value to $498 billion. The stock has returned over 40% year-to-date, fueled by earnings beats, a planned orthopedics spin-out, and steady dividend growth. Institutional investors reported mixed moves, with Schroder trimming its stake and New York State Common Retirement Fund also reducing holdings.

29 November 2025

Dividends·Earnings Reports·NYSE:JNJ·Stock Market

Johnson & Johnson Stock (JNJ) Near Record Highs: Earnings Momentum, Spin‑Off Plans and Talc Risks in 2025

Johnson & Johnson shares closed at $206.92 on November 28, just below their 52-week high of $207.81. The stock is up about 43–47% year-to-date, far outpacing the S&P 500. Oncology sales rose 20.6% in the first nine months of 2025, reaching $18.5 billion. Analyst consensus remains broadly positive, with recent price targets mostly below current levels.

29 November 2025

Earnings Reports·NYSE:JNJ·Stock Market

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Johnson & Johnson shares closed just below a 52-week high near $208 on November 28, giving the company a $500 billion market cap. The stock is up 17.6% over three months and 43% year-to-date, far outpacing the S&P 500. Recent moves include a $3.05 billion Halda Therapeutics acquisition and plans to spin off DePuy Synthes. Norway’s sovereign wealth fund has taken a multibillion-dollar stake.

28 November 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

Previous 1 … 5 6 7 8 Next

Microsoft Stock Falls 4.6% Despite Strong Q3 Earnings and AI Revenue Surge
May 1, 2026, 12:24 AM EDT. Microsoft's stock dropped 4.6% despite reporting better-than-expected Q3 fiscal 2026 results, with earnings of $4.27 per share and sales of $82.9 billion, beating forecasts. The company saw 18% sales growth and a 123% surge in artificial intelligence (AI) revenue to $37 billion, making up nearly half its total revenue. However, massive capital investments of $30.9 billion reduced free cash flow by 22% year-on-year to $15.8 billion for the quarter. With a projected free cash flow valuation multiple around 50 times, some analysts caution about the stock's high price relative to growth. Despite strong growth, investors should weigh the risks and consider analyst recommendations before buying Microsoft shares.

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026

LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:28 AM EDT Microsoft Stock Falls 4.6% Despite Strong Q3 Earnings and AI Revenue Surge May 1, 2026, 12:24 AM EDT. Microsoft's stock dropped 4.6% despite reporting better-than-expected Q3 fiscal 2026 results, with earnings of $4.27 per share and sales of $82.9 billion, beating forecasts. The company saw 18% sales growth and a 123% surge in artificial intelligence (AI) revenue to $37 billion, making up nearly half its total revenue. However, massive capital investments of $30.9 billion reduced free cash flow by 22% year-on-year to $15.8 billion for

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026

Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026

Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.

Go toTop

NYSE:JNJ 28 November 2025 - 11 December 2025

Stock Market Today

Latest article